Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.20.4
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue $ 8,278 $ 17,823 $ 9,469 $ 7,152 $ 11,305 $ 12,277 $ 10,525 $ 8,629 $ 42,722 $ 42,736 $ 38,419
Collaboration and License Agreements and Supply Agreements                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 42,722 42,736 38,419
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 11,407 11,321 21,187
Collaboration and License Agreements and Supply Agreements | Merck                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 26,075 21,458 8,526
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany "EMD Serono")                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 5,042 8,879 7,175
Collaboration and License Agreements and Supply Agreements | Vaxcyte                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 $ 198 $ 1,078 $ 1,531